Effect of polyanion-resistance on HIV-1 infection  by Bobardt, Michael D et al.
www.elsevier.com/locate/yviro
Virology 325 (2004) 389–398Effect of polyanion-resistance on HIV-1 infection
Michael D. Bobardt,a Mercedes Armand-Ugo´n,b Imma Clotet,b Zhe Zhang,c Guido David,c
Jose A. Este,b and Philippe A. Gallaya,*
aDepartment of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
bRetrovirology Laboratory IrsiCaixa, Hospital Germans Trias i Pujol, 08916 Badalona, Spain
cCenter for Human Genetics, University of Leuven and Flanders Interuniversity Institute for Biotechnology, B-3000 Leuven, BelgiumReceived 26 February 2004; returned to author for revision 22 March 2004; accepted 11 May 2004
Available online 17 June 2004Abstract
Polyanions are potent HIV-1 entry inhibitors. Nevertheless, resistant viruses may emerge under polyanion inhibitory pressure.
Specifically, a polyanion-resistant virus replicates in T cells even in the presence of high concentrations of polyanions. We found that
although the polyanion-resistant virus grows in suspension CD4+ T cells efficiently, it infects nonlymphocytic adherent CD4+ cells poorly.
Given that a main distinction between suspension and adherent cells is the absence or presence of cell-surface heparan sulfate proteoglycan
(HSPG), we investigated if the failure of the polyanion-resistant virus to infect adherent CD4+ cells arises from its inability to bind HSPG.
We found that the emergence of mutations in gp120 associated with polyanion resistance resulted in a decreased capacity of HIV-1 to bind
HSPG. We also found that the polycation polybrene rescued the capacity of the polyanion-resistant virus to bind HSPG and to infect adherent
CD4+ cells. The identification of this virus, unable to bind HSPG, provides a convenient probe to measure the impact of HIV-1–HSPG
interactions in vivo. Altogether, these findings suggest that polyanion-resistance narrows the range of potential target cells for HIV-1 in the
host. This reinforces the hypothesis that cell-free or cell-associated polyanions such as HSPG possess the capacity to modulate HIV-1
pathogenesis.
D 2004 Elsevier Inc. All rights reserved.Keywords: Polyanion; HIV-1; T cellIntroduction
Dextran sulfate (DS) exerts an inhibitory effect against
HIV-1 as well as HIV-2 by blocking viral entry (Baba et al.,
1988; Ito et al., 1987; Mitsuya et al., 1988; Ueno and Kuno,
1987). Gp120 represents the main binding target for DS
(Callahan et al., 1991; Mbemba et al., 1992; Schols et al.,
1990). Because DS prevents the recognition of gp120 by
anti-V3 loop antibodies, it strongly suggests that the hyper-
variable V3 loop of gp120 represents a main locus for DS
binding (Callahan et al., 1991; Harrop et al., 1994; Moulard
et al., 2000; Okada et al., 1995). The observations that DS
does not interfere with gp120-CD4 interactions (Callahan et
al., 1991; Mbemba et al., 1992; Moulard et al., 2000), but
interferes with gp120–coreceptor interactions (at least0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: gallay@scripps.edu (P.A. Gallay).CXCR4) (Moulard et al., 2000), are in accordance with
the assumption that the V3 loop serves a main point of
contact between gp120 and the coreceptors CXCR4 and
CCR5 (Kwong et al., 2000). Several lines of evidence
underline the importance of electrostatic interactions bet-
ween positively charged (basic) residues in both the V3 loop
and the conserved coreceptor binding domain of gp120 with
negatively charged (acidic or sulfated) residues located in
the extracellular domain of the coreceptor (Basmaciogullari
et al., 2002; Dragic et al., 1998; Farzan et al., 1998, 1999;
Hatse et al., 2001; Rabut et al., 1998; Wang et al., 1998,
1999). Thus, likely, the direct binding of the negatively
charged polyanion DS to the V3 loop or the conserved
coreceptor binding domains interferes with gp120–corecep-
tor interactions, and therefore prevents efficient HIV-1
fusion and entry.
Previous studies showed that a virus resistant to both
polyanions—DS and the G-quartet forming oligonucleotide
AR177—can be selected in vitro (Este et al., 1997, 1998).
Specifically, the X4 NL4.3 HIV-1 strain was grown in
M.D. Bobardt et al. / Virology 325 (2004) 389–398390suspension CD4+ MT-4 cells in the presence of increasing
concentrations of the above polyanions. The virus recovered
was able to replicate in MT-4 cells even in the presence of
high concentrations of polyanions, whereas wild-type
NL4.3 was unable to replicate under these conditions. The
finding that mutations mainly arose in the gp120 of the
polyanion-resistant virus (Fig. 1A) (de Vreese et al., 1996)
strongly suggests that resistance of HIV-1 to polyanions is
associated with mutations in gp120.
DS resembles the large family of glycosaminoglycans
(GAG) that includes dermatan sulfate, keratan sulfate, hep-
aran sulfate, and chondroitin sulfate (Bernfield et al., 1999).
All these polyanions are capable of modulating HIV-1
infection. Although a majority of soluble GAG in general
exhibits an inhibitory effect on HIV-1 infection (at least for
X4 viruses) (Baba et al., 1988; Bagasra et al., 1991; Callahan
et al., 1991; Mitsuya et al., 1988; Patel et al., 1993), cell-
surface-associated GAG (such as heparan sulfate or chon-
droitin sulfate) in some circumstances exert beneficial
effects on HIV-1 replication. Originally, Norcross et al.
demonstrated that cell-surface heparan sulfates promote
HIV-1 infection in several cell lines (Patel et al., 1993;
Roderiquez et al., 1995). Several groups confirmed these
results by showing that the presence of heparan sulfate
proteoglycan (HSPG) on the surface of specific cell typesFig. 1. (A) Amino acid and net charge comparisons between wild-type and pol
replicates at wild-type levels in T-cell lines even in the presence of inhibitory polya
2 ng of p24 of wild-type or polyanion-resistant NL4.3 viruses (derived from MT-4
Da) was added at concentration of 10 Ag/ml. Viral replication was measured by
experiments.may greatly influence HIV-1 infection (Guibinga et al.,
2002; Mondor et al., 1998; Ohshiro et al., 1996; Saphire et
al., 2001; Zhang et al., 2002). Specifically, Zhang et al. using
a large panel of primary viruses (envelopes) nicely showed
that the presence of cell-surface GAG may either facilitate
HIV-1 infectivity (i.e. X4 viruses) or diminish HIV-1 infec-
tivity (i.e., R5 viruses). Thus, cell-surface GAG possesses
the capacity to exert either a detrimental or beneficial effect
on HIV-1 infection. More recently, we found that HSPG,
especially syndecans, expressed on the surface of the human
endothelium may capture HIV-1 particles, protect them for
several days, and present and transfer them to trafficking T
cells that become ultimately infected (Bobardt et al., 2003).
Furthermore, we and others presented evidence that heparan
and chondroitin sulfates expressed on the surface of brain
microvascular endothelial cells may facilitate HIV-1 trans-
cytosis through the blood–brain barrier (Argyris et al., 2003;
Bobardt et al., 2004; Liu et al., 2002). Altogether, these
observations suggest that although soluble GAG present in
the blood likely inhibits HIV-1 infection (at least X4
viruses), cell-surface GAG abundantly expressed on specific
cells and tissues may facilitate HIV-1 pathogenesis. There-
fore, the capacity of gp120 to bind soluble or cell-associated
GAG may be either beneficial or detrimental for HIV-1
depending on the microenvironment.yanion-resistant V3 loop NL4.3 viruses. (B) The polyanion-resistant virus
nion concentrations. Jurkat or MT-4 cells (0.5  106 cells) were exposed to
cells) for 2 h and washed to remove unbound virus. Dextran sulfate (5000
p24 ELISA every 3 days. Results are representative of two independent
M.D. Bobardt et al. / Virology 325 (2004) 389–398 391In the present study, we analyzed the capacity of a
polyanion-resistant virus to attach to the surface of target
cells via GAG, and to replicate in CD4+ cells that express or
lack GAG. We found that although the polyanion-resistant
virus grows perfectly in suspension T-cell lines such as
Jurkat and MT-4 cells that lack GAG, it poorly infects
adherent target cells that express GAG such as CD4+ HeLa
or GHOST cells. Given that previous studies suggested that
GAG, specifically HSPG, facilitate HIV-1 infection in
specific target cells, we asked if the inability of the poly-
anion-resistant virus to infect CD4+ HeLa and GHOST cells
correlates with a failure to bind to HSPG. We found that in
contrast to wild-type virus, the polyanion-resistant virus
fails to efficiently bind to HSPG. Furthermore, we observed
that the polycation—polybrene—rescues the capacity of the
polyanion-resistant virus to either bind HSPG or to infect
CD4+ HeLa and GHOST cells. Our results suggest that
polyanion resistance narrows the range of potential target
cells for HIV-1 in the host, and further support the notion
that cell-free or cell-associated polyanions such as HSPG
possess the capacity to modulate HIV-1 pathogenesis.Results
Polyanion-resistant HIV-1 efficiently replicates in
suspension CD4+ T cells
We first examined the resistance of the polyanion-resis-
tant NL4.3 virus to DS using suspension CD4+ Jurkat T
cells as well as CD4+ MT-4 cells (Fig. 1B). Wild-type and
polyanion-resistant NL4.3 viruses were added to T cells
together with or without 10 Ag/ml of DS. Twenty-four hours
post-infection, cells were washed twice to remove the initial
inoculum and incubated in fresh medium containing 10 Ag/
ml of DS. Viral replication was monitored every 3 days by
measuring amounts of capsid released into the medium by
p24 ELISA. We found that DS drastically reduces the
growth of wild-type NL4.3 in both Jurkat and MT-4 cells
(Fig. 1B), confirming the efficacious inhibitory effect of the
soluble polyanion. In sharp contrast, we observed that the
growth of the polyanion-resistant NL4.3 was not signifi-
cantly altered by the presence of the polyanion compared to
wild-type growth in the absence of DS (Fig. 1B). We
obtained similar results using other T-cell lines including
MOLT and HUT-78 (data not shown). This demonstrates
that the polyanion-resistant virus is perfectly capable to
resist the inhibitory pressure of DS in several T-cell lines
(Este et al., 1998).
Polyanion-resistant HIV-1 infects adherent CD4+ cells
poorly
After demonstrating that the polyanion-resistant NL4.3
grows at wild-type levels in several suspension CD4+ T-cell
lines, we asked if its resistance to DS extends to non-lymphocytic targets such as adherent CD4+ cells. The major
adherent target cell for HIV-1 in vivo is the macrophage.
Unfortunately, NL4.3 (X4 virus) cannot infect primary
macrophages. Thus, we examined the infectivity of the
polyanion-resistant NL4.3 in adherent CD4+ cells that are
permissive to NL4.3 such as epithelial CD4+ CXCR4+
HeLa cells (called TZM-bl) and osteosarcoma CD4+
CXCR4+ cells (called GHOST). To measure HIV-1 infec-
tivity, we took advantage of the fact that TZM-bl cells
contain h-galactosidase and luciferase reporter genes (Wei
et al., 2002), whereas GHOST cells contain a GFP reporter
gene (Morner et al., 1999). Adherent TZM-bl and GHOST
cells were exposed to wild-type and polyanion-resistant
NL4.3 viruses for 24 h, washed twice to remove viral
inoculum, and incubated at 37 jC for 48 h. To measure
infectivity, TZM-bl cells were stained with Xgal and num-
ber of blue foci counted, whereas GHOST cells were
analyzed for GFP content by FACS. Interestingly, we found
that although the polyanion-resistant NL4.3 is perfectly able
to infect T-cell lines (Fig. 1), it poorly infects both adherent
CD4+ HeLa or GHOST cells compared to wild-type virus
(about 12-fold decrease) (Fig. 2). As above, DS does not
affect the infectivity of the polyanion-resistant NL4.3 virus
in both TZM-bl and GHOST cells (data not shown). This
strongly suggests that the resistance to polyanions is target
cell specific.
Suspension and adherent CD4+ cells express opposite
levels of HSPG and CD4
To understand this difference in susceptibility to the
polyanion-resistant NL4.3 virus, Jurkat, MT-4, CD4+ HeLa,
and GHOST cells were analyzed for their surface expression
of several receptors known to influence HIV-1 attachment or
fusion such as DC-SIGN/R, HSPG, CD4, and CXCR4.
First, we found that all four cell lines express considerable
levels of CXCR4 and no detectable levels of DC-SIGN/R
(Fig. 3). Although the four cell lines express significant
levels of CD4, the two T-cell lines, Jurkat and MT-4,
express higher CD4 levels than the two nonlymphocytic
cell lines, TZM-bl and GHOST. Furthermore, we found that
Jurkat and MT-4 cells express almost undetectable levels of
HSPG, whereas TZM-bl and GHOST cells richly express
HSPG (Fig. 3). Our observation that polyanion-resistant
NL4.3 ‘‘permissive’’ cells (Jurkat and MT-4) express low
HSPG and high CD4 levels, whereas ‘‘nonpermissive’’ cells
(TZM-bl and GHOST) express high HSPG but low CD4
levels, suggests a correlation between refractivity of target
cells to polyanion-resistant NL4.3 and the cell-surface
expression of CD4 and HSPG.
Polyanion-resistant HIV-1 fails to bind to cell-surface
HSPG
To escape polyanion selective pressure, HIV-1 developed
mutations in gp120. We postulated that the polyanion-
Fig. 3. Suspension and adherent CD4+ cells express an opposite pattern of
CD4 and HSPG levels. Jurkat, MT-4, TZM-bl, and GHOST (106 cells),
pretreated or not with heparinase, were incubated with anti-CD4 mAb
SIM.4, anti-DC-SIGN mAb DC28, anti-CXCR4 mAb 12G5, or anti-HSPG
mAb 10E4 (1 Ag) in 500 Al of PBS containing 0.25% human serum. Levels
of cell-surface receptors were determined by FACS analysis. The secondary
antibody control values were subtracted from the test values. Values are the
geometric means expressed in fluorescence units (log scale). Results are
representative of two independent experiments.
Fig. 2. The polyanion-resistant virus infects CD4+ adherent cells poorly.
TZM-bl and GHOST (0.25  106 cells) cells were exposed to 2 ng of p24
for 2 h and washed to remove unbound virus, and viral infection was
measured 48 h post-infection by Xgal staining for TZM-bl cells and by GFP
content by FACS for GHOST cells. For GHOST cells, values are the
geometric means expressed in fluorescence units (log scale). Results are
representative of two independent experiments.
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HSPG. The major members of the HSPG family are the
syndecans (Bernfield et al., 1999). Syndecans are trans-
membrane proteins with an ectodomain that bears three
anionic heparan sulfate chains (Bernfield et al., 1999). There
are four syndecan members that all possess the capacity to
bind HIV-1 (Bobardt et al., 2003, Saphire et al., 2001). We
compared the capacity of the polyanion-resistant NL4.3
virus to bind cell-surface syndecans with that of wild-type
NL4.3. Parental CD4-negative Namalwa B cells, syndecan-
transfected cells (Namalwa B cells stably transfected with
human syndecan-2), and DC-SIGN-transfected cells
(Namalwa B cells stably transfected with human DC-SIGN)
were exposed to wild-type or polyanion-resistant NL4.3
viruses for 2 h at 37 jC as described previously (Bobardt
et al., 2003). Cell-surface expression of syndecan-2 and DC-
SIGN was verified before the attachment assay as described
previously (Bobardt et al., 2003). Cells were then washed
and lysed. Amounts of bound virus were determined by
measuring HIV-1 capsid content in cell lysate by p24
ELISA. No capsid internalization occurs under these con-ditions (data not shown). Although no binding was observed
with parental cells, wild-type and polyanion-resistant NL4.3
viruses bind equivalently well to DC-SIGN+ cells (Fig. 4A).
In sharp contrast, the polyanion-resistant NL4.3 virus binds
poorly to syndecan+ cells compared to wild-type virus. One
explanation for this failure to bind HSPG is that the
polyanion-resistant NL4.3 virus contains less gp120 than
wild-type virus. Thus, we compared the amounts of gp120
incorporated into wild-type and polyanion-resistant NL4.3
viruses. We found that both viruses packaged similar
amounts of gp120 (Fig. 4B) eliminating this parameter to
explain the difference in syndecan binding between the two
viruses. The observation that both viruses bind equivalently
well to DC-SIGN further supports the notion that they
contain similar levels of gp120.
Polybrene rescues polyanion-resistant HIV-1 binding to
HSPG and infectivity of adherent CD4+ cells
We showed that in contrast to wild-type NL4.3, the
polyanion-resistant NL4.3 virus had reduced binding to
cell-surface HSPG. Given that the polyanion-resistant
NL4.3 virus poorly infects cells that express low CD4 but
high HSPG levels such as TZM-bl and GHOST, we postu-
lated that this failure arises from the inability of the poly-
anion-resistant NL4.3 virus to bind these cells via HSPG.
Previous studies suggested that cell-surface HSPG exert
Fig. 5. Polybrene rescues polyanion-resistant virus capacities to bind to
cell-surface HSPG and to infect CD4+ adherent cells. (A) Syndecan-2+
Namalwa B cells (0.25  106 cells) were exposed to wild-type and
polyanion-resistant NL4.3 viruses (derived from MT-4 cells) (1 ng of p24)
for 2 h at 37 jC in the presence of increasing concentrations of polybrene,
washed, and lysed, and p24 content was measured by ELISA. Results
(duplicates) are expressed in percentage of p24 captured relative to the
initial inoculum. This experiment is representative of two independent
experiments. (B) TZM-bl (0.25  106 cells) cells were exposed to 2 ng of
p24 for 2 h in the presence or absence of polybrene and washed to remove
unbound virus, and viral infection was measured 48 h post-infection by
Xgal staining. Values (duplicates) are expressed in number of blue foci per
ng of p24.
Fig. 4. The polyanion-resistant virus lost its capacity to bind to cell-surface
HSPG. (A) Parental Namalwa B cells, syndecan-2+ cells, and DC-SIGN+
cells (0.25  106 cells) were exposed to wild-type or polyanion-resistant
NL4.3 viruses (derived from MT-4 cells) (1 ng of p24) for 2 h at 37 jC,
washed, and lysed, and p24 content was measured by ELISA. Results
(duplicates) are expressed in percentage of p24 captured relative to the
initial inoculum. This experiment is representative of two independent
experiments. (B) Amounts of gp120 of wild-type, polyanion-resistant and
gp160-deficient NL4.3 viruses (2 ng of p24) were measured by ELISA.
Values (triplicates) are expressed in pg of gp120 per ng of p24. Results are
representative of two independent experiments.
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the initial viral adsorption onto the surface of specific cell
types (Mondor et al., 1998; Patel et al., 1993; Roderiquez et
al., 1995; Saphire et al., 2001). In this scenario, more
infectious particles accumulate at the surface of the target
cell favoring the encounter between the virus and the entry
receptors—CD4 and the coreceptors. Thus, if the polyanion-
resistant NL4.3 virus poorly infects TZM-bl and GHOST
cells simply due to a failure to attach via HSPG, one can
imagine that by forcing or promoting the initial viral
adsorption, this would rescue its infectivity. Given that
previous work showed that the polycation polybrene pro-
motes HIV-1 attachment to the surface of target cells
(O’Doherty et al., 2000), we asked if polybrene by enhanc-
ing the polyanion-resistant NL4.3 virus attachment would
rescue its infectivity in TZM-bl and GHOST cells. We first
examined if polybrene restores the polyanion-resistant
NL4.3 virus binding to HSPG. We found that the presenceof polybrene does not alter the capacities of wild-type and
polyanion-resistant NL4.3 viruses to bind to DC-SIGN+ or
parental cells that lack HSPG (data not shown). Interesting-
ly, although polybrene (10 Ag/ml) slightly enhanced wild-
type binding, it strongly promoted the binding of the
polyanion-resistant NL4.3 virus to cell-surface syndecans
(Fig. 5A). This suggests that the presence of the polycation
totally rescues the capacity of the polyanion-resistant NL4.3
virus to bind to HSPG. After identifying conditions that
restore the attachment of the polyanion-resistant NL4.3
virus to HSPG, we examined the effect of increasing
concentrations of polybrene on the infectivity of the poly-
anion-resistant NL4.3 virus in TZM-bl cells. Importantly,
we found that although wild-type infectivity was slightly
enhanced, the polybrene dramatically enhanced the infec-
M.D. Bobardt et al. / Virology 325 (2004) 389–398394tivity of the polyanion-resistant NL4.3 virus (Fig. 5B). Note
that at the highest concentration (20 Ag/ml), polybrene
exerts an inhibitory effect on wild-type infectivity (data
not shown). We obtained similar results using GHOST cells
as targets (data not shown). Importantly, polybrene (1–10
Ag/ml) has no major effect on wild-type and polyanion-
resistant NL4.3 virus replication in the two CD4+ T-cell
lines, MT-4 and Jurkat, which express low HSPG but high
CD4 levels (data not shown). Thus, our data indicate that
there is a direct correlation between the incapacity of the
polyanion-resistant NL4.3 virus to bind to HSPG and its
incapacity to efficiently infect adherent CD4+ target cells.
The presence of HSPG on adherent target cells does not
represent an obstacle for polyanion-resistant HIV-1
infection
We showed that the polyanion-resistant NL4.3 virus fails
to efficiently infect adherent cells, which express high
HSPG levels, such as TZM-bl and GHOST cells (Fig. 3).
One simple explanation is that cell-surface HSPG exert a
detrimental effect on polyanion-resistant NL4.3 virus entry
into CD4+ adherent cells. To address this issue, bothFig. 6. The removal of HSPG from CD4+ adherent cells does not rescue the in
pretreated or not with heparinase (10U) were exposed to 2 ng of p24 of wild-type
washed to remove unbound virus. Viral replication was measured by p24 ELISA e
TZM-bl (0.25  106 cells) cells pretreated or not with heparinase (10U) were exp
infection was measured 48 h post-infection by Xgal staining. Results are represesuspension (MT-4) and adherent (TZM-bl) target cells were
pretreated with heparinase to remove cell-surface heparan
sulfate moieties as described previously (Saphire et al.,
2001). The removal of cell-surface HSPG was verified by
FACS (80% removed) (Fig. 3). As expected, we found that
the removal of HSPG from the surface of T cells does not
affect the replication of wild-type and polyanion-resistant
NL4.3 viruses (Fig. 6A). By contrast, wild-type infectivity
was reduced in CD4+ adherent cells after HSPG removal
(Fig. 6B), suggesting that HSPG on the surface of TZM-bl
facilitates NL4.3 infection, likely by promoting viral ad-
sorption as previously suggested (Mondor et al., 1998;
Saphire et al., 2001). Note that chondroitinase treatment
that removes another class of GAG—chondroitin sulfate
proteoglycans—does not influence HIV-1 infection as pre-
viously reported (data not shown; Mondor et al., 1998;
Saphire et al., 2001). However, the removal of HSPG on
TZM-bl cells did not rescue the infectivity of the poly-
anion-resistant NL4.3 virus, indicating that the presence of
cell-surface HSPG is not detrimental to the infectivity of
the resistant mutant virus in CD4+ adherent cells. Note that
we obtained similar results using Jurkat and GHOST cells
(data not shown).fectivity of the polyanion-resistant virus. (A) MT-4 cells (0.5  106 cells)
or polyanion-resistant NL4.3 viruses (derived from MT-4 cells) for 2 h and
very 3 days. Results are representative of two independent experiments. (B)
osed to 2 ng of p24 for 2 h and washed to remove unbound virus, and viral
ntative of two independent experiments.
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In the present study, we showed that although a poly-
anion-resistant virus perfectly replicates in several T-cell
lines, it exhibits reduced infectivity in adherent nonlympho-
cytic CD4+ cell targets such as TZM-bl and GHOST cells.
This finding strongly suggests that the apparent robustness
of the polyanion-resistant virus strictly depends on the type
of target cells used. We asked why the polyanion-resistant
virus is unable to efficiently infect TZM-bl and GHOST
cells. We found that ‘‘nonpermissive’’ adherent TZM-bl and
GHOST cells express high HSPG but low CD4 levels,
whereas ‘‘permissive’’ MT-4 and Jurkat cells express low
HSPG but high CD4 levels, suggesting a correlation bet-
ween HSPG and CD4 expression and the permissivity of the
target cells to the polyanion-resistant virus. We then postu-
lated that HIV-1, to rapidly evade the polyanion selective
pressure, mutated its glycoprotein in a way that gp120 is no
longer recognized by polyanions. Corroborating this hy-
pothesis, we found that the polyanion-resistant virus fails to
bind HSPG. We also showed that the presence of polybrene,
an agent that forces HIV-1 attachment onto the surface of
target cells, restores the capacity of the polyanion-resistant
virus to bind HSPG. Polybrene also rescues the infectivity
of the polyanion-resistant virus in TZM-bl and GHOST
cells. Altogether, our data strongly suggest that the resis-
tance to polyanions somewhat altered the gp120 of the
polyanion-resistant virus in a manner that preserves its
capacity to infect T cells, but diminishes its capacity to
infect adherent CD4+ cells.
A question that arises from these findings is why is the
polyanion-resistant virus capable of infecting suspension
CD4+ cells but unable to infect adherent CD4+ target cells?
Because we showed that the polyanion-resistant virus can-
not bind to HSPG, the simplest scenario to explain its failure
to infect CD4+ adherent cells is that HSPG serve as
attachment receptors. The low amounts of CD4 on TZM-
bl and GHOST might be insufficient to mediate the initial
adsorption of the virus, and ancillary interactions, such as
HSPG–gp120 interactions, are necessary for successful
attachment and viral entry. Supporting this hypothesis,
polybrene rescued the infectivity of the polyanion-resistant
virus into TZM-bl and GHOST cells. Alternatively, the
mutations in gp120 that confer resistance to polyanions
subtly diminish the affinity of gp120 to CD4. In this
scenario, the low CD4 levels on TZM-bl and GHOST cells
would magnify this deficit, whereas on T cells, the high
CD4 levels would mask this handicap. Lastly, we cannot
rule out the possibility that HSPG do not serve as attach-
ment receptors, rather they favor CD4–gp120–coreceptor
interactions necessary for successful fusion. Because HSPG
bind the V3 loop of gp120, they also may modulate gp120–
coreceptor interactions by altering electrostatic contacts
between the positive charges of V3 loop and the corecep-
tor-binding domain of gp120 and the negative charges of the
extracellular domain of the coreceptor.The inability of polyanion-resistant viruses to infect
adherent CD4+ cells may not represent a major obstacle
for X4 viruses given that with the exception of macro-
phages, no adherent CD4+ cells exist in humans. By
contrast, the incapacity of R5 viruses to infect macrophages
due to polyanion resistance may have profound effect on
HIV-1 pathogenesis. It would be interesting to select poly-
anion-resistant R5 viruses and to examine the capacities of
emerging mutant viruses to infect macrophages. Neverthe-
less, it is important to note that in terms of CD4 levels,
HSPG levels and contribution of HSPG to HIV-1 infection,
we observed similar behavior between primary human
macrophages, TZM-bl, and GHOST cells (Saphire et al.,
2001).
Several studies showed that R5 viruses are more resis-
tant against the inhibitory effect of polyanions than X4
viruses (Meylan et al., 1994; Moulard et al., 2000; Zhang et
al., 2002). In this model, the highly positive charged V3
loop of X4, in contrast to the low positive charged V3 loop
of R5 virus, represents an ideal ligand for polyanions,
resulting in a strong interference with gp120–CXCR4
interactions. Another scenario that would explain why R5
viruses are less sensitive to polyanion inhibition is simply
that their fusion capacity is superior to that of X4 viruses.
Supporting this hypothesis, R5 viruses are 10-fold more
resistant to the fusion inhibitory peptide T-20 than X4
viruses (Derdeyn et al., 2001; Xu et al., 2000). If R5
viruses truly fuse more rapidly than X4 viruses, this would
lessen the chance of polyanions to exert its inhibitory
action on R5 infection. Note that the original observation
by Meylan et al. (1994), that the infectivity of R5 viruses is
not diminished (rather enhanced) by polyanions, was ex-
clusively observed using macrophages as targets. Indeed,
polyanions blocked R5 virus infectivity in PBMCs (Meylan
et al., 1994). Given that macrophages, in contrast to
PBMCs, express high HSPG levels (Saphire et al., 2001),
this suggests that the inhibitory effect of polyanions on
HIV-1 infection is reduced when target cells express HSPG.
This further suggests that HIV-1 sensitivity to polyanions is
not simply V3 loop charge specific, but also target cell type
specific.
Although the polyanion-resistant virus still replicates in
T-lymphocytes, its inability to bind HSPG may exert a
detrimental effect on the progress of pathogenesis. For
example, HSPG on the surface of the genital epithelium
may promote HIV-1 sexual transmission, HSPG on the
surface of macrophages may facilitate the establishment of
long-term viral reservoirs (Saphire et al., 2001), and HSPG
by capturing and protecting HIV-1 for several days onto the
surface of the endothelium (Bobardt et al., 2003) may
facilitate the escape of the virus toward the immune
response. Furthermore, we and others presented several
lines of evidence that proteoglycans on the surface of the
blood–brain barrier may facilitate the invasion of HIV-1
into the brain (Argyris et al., 2003; Bobardt et al., 2004;
Liu et al., 2002). Therefore, the identification of a mutant
M.D. Bobardt et al. / Virolog396virus unable to bind HSPG, such as the polyanion-resistant
virus examined in this study, provides a convenient probe
to measure the impact of HIV-1–HSPG interactions in
vivo. To our knowledge, this is the first description of a
virus that displays such a disparate infectivity with respect
to target cell type.Material and methods
Cells
Human Jurkat T cells (generously contributed by ATCC
and Dr. Arthur Weiss), MT-4 T cells (generously contribu-
ted by Dr. Douglas Richman), CD4+ CXCR4+ GHOST
cells (CD4+ osteosarcoma cells) (generously contributed by
Dr. Vineet KewalRamani and Dr. Dan Littman), and TZM-
bl (CD4+ HeLa cells) (generously contributed by Dr. John
C. Kappes, Dr. Xiaoyun Wu, and Tranzyme Inc.) were
obtained through the AIDS Research and Reference
Reagent Program. Parental Namalwa B cells, syndecan-2-
transfected Namalwa cells, and DC-SIGN-transfected
Namalwa cells were generated as described previously
(Bobardt et al., 2003).
FACS analyses
One million cells were incubated with antibodies (1 Ag)
in 500 Al of PBS containing 0.25% human serum. Anti-
CD4 mAb SIM.4 (generously contributed by Dr. James
Hildreth), anti-DC-SIGN mAb DC28 (generously contribu-
ted by Drs. F. Baribaud, S. Pohlmann, J.A. Hoxie, and
R.W. Doms), and anti-CXCR4 mAb 12G5 (generously
contributed by Dr. James Hoxie) were obtained through
the AIDS Research and Reference Reagent Program. Anti-
HSPG mAb 10E4 was obtained from Seikagaku. Adherent
TZM-bl and GHOST cells were detached with Cell Striper
(Mediatech Inc.).
Infections
The polyanion-resistant virus (NL4.3-derived) was gene-
rated by Este et al. (1997) as previously described. Viral
load was standardized by p24 antigen by ELISA (Perkin
Elmer Life Sciences). Jurkat and MT-4 cells (0.5  106
cells) were exposed to 2 ng of p24 for 2 h and washed to
remove unbound virus, and viral replication was measured
by p24 ELISA every 3 days. TZM-bl and GHOST cells
were exposed to 2 ng of p24 for 2 h and washed to remove
unbound virus, and viral infection was measured 48 h post-
infection by h-galactosidase (Xgal staining) for TZM-bl
cells and by GFP (FACS) content for GHOST cells.
Dextran sulfate 5000 Da (Sigma) was used at concentration
from 1 to 10 Ag/ml. Heparinase (10 U) (Sigma) treatment
(2 h at 37 jC) was performed as described previously
(Saphire et al., 2001).Attachment assay
Virus binding assay was performed as described previ-
ously (Bobardt et al., 2003; Pohlmann et al., 2001). In brief,
Namalwa cells (0.25  106 cells/500 Al complete RPMI)
were exposed to NL4.3 (1 ng of p24) for 2 h at 37 jC,
washed three times with 3 ml of PBS, lysed in Triton X-100,
and p24 content in cell lysate was measured by ELISA
(Perkin Elmer Life Sciences).
Gp120 ELISA
ELISA (96-well) plates (Immulon, Thermo Labsystem)
were coated overnight at 37 jC with recombinant human
anti-gp120 2G12 IgG (2 Ag/ml in PBS) (generously contrib-
uted by Dr. Hermann Katinger) obtained through the AIDS
Research and Reference Reagent Program. Plates were
washed twice with PBS, blocked for 1 h at 37 jC in 5%
FCS in PBS, and washed four times with 0.2% Tween 20 in
PBS. Lysed viruses (samples diluted in 10% FCS, 0.5%
TX100 in PBS) or recombinant gp120 (standard curve from
0 to 10 ng/ml) (obtained through the AIDS Research and
Reference Reagent Program and generously contributed by
DAIDS and NIAID) were added to the plates for 2 h at 37
jC. Plates were washed four times with 0.2% Tween 20 in
PBS. Rabbit polyclonal anti-gp120 serum (Intracel) was
added to the plates at a dilution of 1/5000 in 10% FCS,
0.5% TX100 in PBS for 1 h at 37 jC. Plates were washed
four times with 0.2% Tween 20 in PBS. Anti-rabbit-HRP
(Pierce) was added to the plates at a dilution of 1/5000 in
10% FCS, 0.5% TX100 in PBS for 1 h at 37 jC. Plates were
washed four times with 0.2% Tween 20 in PBS. After adding
the substrate for 30 min at room temperature, the reaction
was stopped with 4 N H2SO4. Plates were read at 450 nm
with a reference at 650 nm.
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